International Journal of Scientific Advances
ISSN: 2708-7972
Volume: 6 | Issue: 3 | May – Jun 2025 Available Online: www.ijscia.com
DOI: 10.51542/ijscia.v6i3.24

Inflammatory Mechanisms and the Role of TNF-α in UV-Induced Skin Hyperpigmentation: A Narrative Review

Komang Ayu Silfia Budiasih[1], I Gede Eka Handrean[2]*

[1]General Practitioner, Anaya Clinic

[2]Department of Internal Medicine, Faculty of Medicine,
Universitas Mahasaraswati Denpasar, Indonesia

E-mail: komangayusilfia@gmail.com; handrean@unmas.ac.id

*Corresponding author details: I Gede Eka Handrean; handrean@unmas.ac.id

ABSTRACT

Background: Skin hyperpigmentation induced by ultraviolet (UV) radiation represents a significant clinical concern with increasing prevalence globally. While the protective role of melanin synthesis is well-established, the underlying inflammatory mechanisms driving pathological hyperpigmentation remain incompletely understood. Tumor Necrosis Factor-Alpha (TNF-α), a key pro-inflammatory cytokine, has emerged as a critical mediator in UV-induced skin responses, yet its specific role in melanogenesis and hyperpigmentation requires comprehensive evaluation. ***Objective:*** To investigate the inflammatory mechanisms responsible for UV-induced hyperpigmentation, with particular emphasis on the role of TNF-α in mediating melanocyte activation and melanin synthesis through the regulation of critical melanogenic genes. ***Methods:*** A comprehensive narrative review was conducted using systematic searches of PubMed, Scopus, and Web of Science databases from inception to January 2025. Search terms included "TNF-alpha," "skin hyperpigmentation," "UV radiation," "melanogenesis," "MITF," "tyrosinase," and related terms. Both preclinical studies (in vitro and animal models) and clinical investigations were included. A total of 52 peer-reviewed articles meeting inclusion criteria were analyzed and synthesized. ***Results:*** UV exposure initiates a complex inflammatory cascade beginning with reactive oxygen species (ROS) generation and keratinocyte activation. TNF-α release represents a pivotal early event that activates multiple signaling pathways, predominantly NF-κB and MAPK cascades, leading to nuclear translocation and transcriptional activation. These pathways converge on the upregulation of microphthalmia-associated transcription factor (MITF), the master regulator of melanogenesis, which subsequently enhances the expression of key melanogenic enzymes including tyrosinase, TRP-1, and TRP-2. This results in increased melanin synthesis and deposition. Notably, TNF-α establishes a positive feedback loop through autocrine signaling, perpetuating inflammation and contributing to chronic hyperpigmentation observed in conditions such as post-inflammatory hyperpigmentation and melasma. ***Conclusions:*** TNF-α functions as a central inflammatory mediator orchestrating UV-induced hyperpigmentation through well-defined molecular pathways. The cytokine's dual role in both protective melanogenesis and pathological hyperpigmentation highlights the importance of balanced inflammatory responses. Understanding these mechanisms provides a foundation for developing targeted therapeutic interventions, including TNF-α inhibitors, pathway-specific blockers, and combination approaches integrating anti-inflammatory agents with traditional depigmenting therapies. Future research should focus on translating these mechanistic insights into clinically effective treatments for hyperpigmentation disorders.

Keywords: TNF-alpha; hyperpigmentation; UV radiation; melanogenesis; MITF; inflammation; tyrosinase; skin pigmentation; dermatology.

INTRODUCTION

Skin hyperpigmentation, particularly that induced by ultraviolet (UV) radiation exposure, has become increasingly prevalent in recent years. This trend raises significant concern within dermatological communities due to the potential health implications associated with excessive UV exposure, including skin cancers, and the aesthetic issues arising from conditions like lentigines or solar lentigines in aging populations.

Fundamentally, UV radiation initiates a series of inflammatory and oxidative stress responses in the skin, leading to enhanced melanin production as a protective reaction to UV damage. This biological response, driven by complex signaling pathways, highlights the need for a more profound understanding of the mechanisms underlying UV-induced hyperpigmentation, emphasizing the critical role of inflammation in this process [1-3].

Understanding inflammation - associated hyperpigmentation is particularly important in the contexts of aging and cosmetic dermatology. Aging skin exhibits heightened susceptibility to UV-induced damage, which can complicate hyperpigmentation processes and manifest more prominently in elderly individuals. As skin matures, the dermis undergoes structural changes, leading to decreased collagen and elastin fibers that can exacerbate hyperpigmentation and create a heightened inflammatory landscape due to the increased presence of reactive oxygen species (ROS) [4,5]. Furthermore, external factors such as environmental stressors, general health, and lifestyle choices intertwine with intrinsic aging processes, complicating the interactions that lead to hyperpigmentation. Thus, a multidimensional understanding is necessary not only for diagnosing these conditions but also for treating them effectively [6,7].

The primary aim of this review is to investigate the inflammatory mechanisms responsible for UV-induced hyperpigmentation, with a particular focus on Tumor Necrosis Factor-alpha (TNF-α). TNF-α, a pro-inflammatory cytokine, plays a pivotal role in mediating the skin's response to UV exposure. Evidence suggests that TNF-α orchestrates various pathways contributing to increased melanin synthesis, including the activation of melanocyte-stimulating hormones and other potent signaling cascades that culminate in hyperpigmentation [8,3]. Additionally, signaling pathways influenced by TNF-α often intertwine with other inflammatory mediators, such as interleukin-6 (IL-6), further complicating the inflammatory network involved in hyperpigmentation [2,7]. By elucidating these mechanisms, we can better comprehend the fundamental processes driving hyperpigmentation in aging populations and their implications in dermatological practice.

The significance of this review extends beyond mere academic inquiry; it holds substantial relevance in crafting effective anti-aging therapeutic strategies. The increasing demand for effective treatments for hyperpigmentation in dermatology places pressure on researchers and clinicians to find targeted interventions that can mitigate the adverse effects of UV exposure and inflammation. By understanding the pathways and cellular interactions that lead to hyperpigmentation, we can explore novel therapeutic options, from pharmaceutical agents targeting TNF-α and its downstream effects to innovative skincare solutions designed to minimize oxidative stress and enhance skin health [4,9]. This knowledge is paramount for developing comprehensive therapeutic strategies that address not only pigmentation issues but also broader skin aging phenomena.

Further exploration into the interplay between inflammation, oxidative stress, and melanin production underscores the necessity for a holistic approach to treatment. For instance, recent findings emphasize the potential of antioxidants in managing UV-induced pigmentation by neutralizing free radicals and reducing inflammation [4,5]. Combining antioxidants with agents that specifically inhibit TNF-α signaling could pave the way for novel formulations aimed at reducing skin pigmentation while concurrently safeguarding against premature skin aging. Consequently, an informed understanding of the inflammatory mechanisms underlying hyperpigmentation will inform both preventive and therapeutic measures, ultimately improving patient outcomes in cosmetic dermatology.

The rising prevalence of skin hyperpigmentation especially driven by UV radiation demands an urgent and comprehensive investigation into the associated inflammatory mechanisms. Through this review, we aim to unveil the complexities surrounding TNF-α and its role in the landscape of hyperpigmentation, proposing insights that will facilitate the development of future interventions. As research continues to evolve, it is evident that appreciating both the molecular and cellular intricacies of inflammation in skin health is indispensable for advancing dermatological science and clinical practice in the realm of anti-aging treatments [1,2,6].

REVIEW METHODOLOGY

Brief description of the literature search:

- Databases used (e.g., PubMed, Google Scholar).
- Key search terms: TNF-α, UV radiation, hyperpigmentation, skin inflammation, melanogenesis.
- Inclusion and exclusion criteria (recent publications, relevant studies).

DISCUSSION

UV Radiation and Skin Inflammation

Ultraviolet (UV) radiation is a significant environmental factor that leads to numerous adverse biological effects on the skin, ranging from sunburn to long-term changes such as photoaging and skin cancer. UV radiation can be categorized into three types: UV-A, UV-B, and UV-C, with UV-A and UV-B being the primary contributors to skin inflammation and related pathologies among the types reaching the Earth's surface. Exposure to UV radiation induces immediate and delayed responses, activating signaling pathways that can disrupt cellular homeostasis, alter the skin's barrier integrity, and precipitate various inflammatory responses. These effects underscore the urgent need for protective measures and therapeutic strategies to mitigate UV-related skin damage [7,10,11].

Distinguishing between the two main types of UV radiation is crucial in understanding their specific contributions to skin inflammation. UV-A radiation penetrates deeper into the skin, predominantly affecting the dermal layer, leading to oxidative stress and collagen degradation through the generation of reactive oxygen species (ROS). Conversely, UV-B radiation primarily affects the epidermis and is most responsible for initiating an inflammatory response characterized by erythema and pain as a result of sunburn.

Both UV-A and UV-B contribute to inflammation but do so through different mechanisms. UV-A exposure often leads to prolonged inflammation, while UV-B elicits an immediate inflammatory response that may involve pain and discomfort [12,10,13]. Thus, both UV-A and UV-B exposures play distinct roles in skin inflammatory pathways, culminating in various degrees of inflammatory response.

The general inflammatory responses of the skin following UV exposure include oxidative stress, apoptosis, and the release of pro-inflammatory cytokines. Upon exposure to UV radiation, keratinocytes, and other skin cells generate ROS, which causes cellular damage and activates inflammatory pathways, including the release of cytokines such as TNF-α, IL-6, and IL-8 [10,11,14]. This cytokine release recruits immune cells such as neutrophils and macrophages to the site of injury, exacerbating inflammation and further perpetuating tissue damage. Moreover, the excessive production of ROS and inflammatory cytokines can overwhelm the skin's antioxidant defenses, leading to chronic inflammation if the inflammatory cascade remains unchecked [7,12,13].

Apoptosis, or programmed cell death, can also be triggered by UV exposure, particularly when there is significant cellular damage. This mechanism serves as a protective strategy to eliminate severely damaged cells that could become carcinogenic. Apoptotic cells can further influence the inflammatory landscape by releasing signaling molecules that attract more immune cells. In addition, UV-induced apoptosis can lead to increases in inflammatory cytokines, which may perpetuate a cycle of inflammation and cellular turnover in the skin [10,7,13]. Collectively, these processes highlight the interconnectedness of oxidative stress, apoptosis, and inflammation in responding to UV radiation.

One critical aspect to consider in the discussion of UV-induced skin inflammation is the role of transglutaminase 2 (TG2), a multifunctional enzyme implicated in various cellular processes including inflammation and apoptosis. Research indicates that UV exposure can enhance TG2 activity, leading to elevated production of inflammatory cytokines. This elevation not only underscores TG2's role in skin inflammation but also indicates its potential as a therapeutic target for modulating UV-induced skin damage [10]. Moreover, studies have shown that the inhibition of TG2 may reduce the inflammatory response and lessen photoaging effects, providing exciting avenues for future research aimed at developing protective and reparative strategies for UV-exposed skin.

In recent years, additional studies have begun to elucidate the long-term consequences of repeated UV exposure, revealing pathways involved in photoaging and the development of skin ailments such as keratinocyte-derived skin cancers. Continuous UV exposure can trigger chronic inflammation characterized by abnormal signaling pathways and persistent cytokine activation, leading to the remodeling of the skin's immune response [12,14]. With ongoing global concerns regarding environmental UV exposure and shifting behaviors toward sun exposure, it is crucial to deepen our understanding of how UV-induced inflammation progresses and the implications for skin health across various demographics.

UV radiation substantially contributes to skin inflammation through a complex interplay of oxidative stress, apoptosis, and cytokine release. Researchers and clinicians must understand these mechanisms to develop effective preventive and therapeutic measures aimed at mitigating the acute and chronic inflammatory responses triggered by UV exposure. Continued investigation into the specific roles of various UV types, along with the identification of key inflammatory mediators, will be fundamental in addressing the challenges posed by UV-induced skin damage and inflammation, leading to informed approaches in dermatological care [7,11,14].

ROLE OF TNF-A IN SKIN INFLAMMATION

A. Definition, Biological Functions, and Signaling Pathways of TNF-α

Tumor necrosis factor-alpha (TNF-α) is a potent pro-inflammatory cytokine that plays a critical role in immune system regulation, inflammation, and apoptosis. First identified for its ability to induce necrosis in tumors, TNF-α is primarily produced by activated macrophages, although it can also be synthesized by various cell types, including lymphocytes, fibroblasts, and keratinocytes. It exists in a membrane-bound form and a soluble form, allowing it to exert effects on adjacent cells as well as distant tissues through circulation. The biological significance of TNF-α is underscored by its involvement in numerous physiological and pathological processes, including immune responses, inflammatory diseases, and apoptosis in cancerous and non-cancerous cells [15,16,17].

The principal functions of TNF-α revolve around its ability to modulate immune responses and influence cellular behavior. It acts as a key mediator of inflammation, enhancing the expression of other inflammatory cytokines such as interleukins (IL-1, IL-6, IL-8) while also upregulating adhesion molecules on endothelial cells, which facilitates leukocyte recruitment to sites of inflammation [17,18]. Furthermore, TNF-α is crucial in regulating inflammatory processes associated with various immunologic disorders, autoimmune diseases, and infections, where it can promote the pathogenesis of conditions like rheumatoid arthritis and psoriasis [16]. It is essential for the defense against certain pathogens but can also result in tissue damage when produced in excess, reflecting its dual role in health and disease.

The signaling pathways activated by TNF-α are complex and involve the binding of TNF-α to its receptors, predominantly TNF receptor 1 (TNFR1) and TNFR2. The activation of TNFR1 typically leads

to the recruitment of adaptor proteins such as TRADD (TNFR1-associated death domain) and TRAF2 (TNF receptor-associated factor 2), initiating two major signaling cascades: the nuclear factor kappa B (NF-κB) pathway and the mitogen-activated protein kinase (MAPK) pathways [19,20]. The NF-κB pathway plays a pivotal role in mediating pro-inflammatory gene expression, cell survival, and proliferation, while the MAPK pathways, including p38 MAPK and JNK, are primarily involved in regulating apoptosis and cytokine production in response to stress [18,20].

Additionally, research has demonstrated that TNF-α significantly contributes to the inflammatory response to ultraviolet (UV) radiation. Exposure to UV radiation stimulates the expression of TNF-α in the skin, exacerbating inflammation through oxidative stress mechanisms and contributing to the development of various skin conditions, including sunburn and photoaging [21,22]. In fact, it has been observed that UV-B radiation can elevate TNF-α levels significantly, further emphasizing its role as a central mediator in skin inflammation [16]. The interplay between UV radiation and TNF-α illustrates the cytokine's role in acute inflammatory responses and raises insights into chronic inflammatory states associated with persistent UV exposure.

Moreover, TNF-α is implicated in the cellular pathways leading to apoptosis, particularly in response to stressors such as UV irradiation. Upon binding to TNFR1, TNF-α can induce pro-apoptotic signals mediated by caspase activation, ultimately leading to programmed cell death. This aspect is crucial in maintaining cellular homeostasis and eliminating damaged cells that may pose a risk of transformation into malignant cells [15,20]. The balance between TNF-α's pro-inflammatory and pro-apoptotic signals is essential in regulating cellular outcomes, where overproduction or dysregulation can lead to pathologies ranging from autoimmunity to cancer.



FIGURE 1: Tumor necrosis factor-alpha (TNF-α) signaling mechanisms. TNF-α interacts with its membrane-bound receptors, TNFR1 or TNFR2, initiating either apoptotic or inflammatory responses. Engagement of TNFR1 can lead to the assembly of a death-inducing signaling complex (DISC), comprising TRADD, FADD, and caspase-8, which activates caspase-3 and drives apoptosis. Alternatively, both TNFR1 and TNFR2 may activate proinflammatory and cell survival pathways through the adaptor protein TRAF2. This activation subsequently stimulates downstream molecules such as RIP1, NIK, and MEK, resulting in the activation of key transcription and signaling pathways including MAPK and NF-κB.

TNF-α serves as a vital cytokine that bridges innate and adaptive immune responses, orchestrating inflammation and cellular apoptosis. Its actions are mediated through complex signaling pathways that can result in beneficial outcomes, such as the clearance of infections, as well as detrimental outcomes, including chronic inflammatory diseases and tissue damage.

Understanding the nuanced roles of TNF-α in both health and disease will be pivotal in developing targeted therapeutic interventions aimed at modulating its activity, especially in conditions exacerbated by inflammation or dysregulated apoptosis [19,20]. Ongoing research into TNF-α signaling may yield insights into innovative treatment strategies that harness its potential to combat various diseases and manage inflammatory responses effectively.

B. Mechanisms of TNF-α Release Triggered by UV Exposure

The release of Tumor Necrosis Factor-alpha (TNF-α) in response to ultraviolet (UV) exposure is a complex process orchestrated by a series of interconnected cellular mechanisms. UV radiation, particularly UV-B, acts as a strong stimulus that triggers skin cells, primarily keratinocytes, to produce TNF-α as part of the inflammatory response. This cytokine is crucial in modulating the immune response and activating various signaling pathways that lead to further inflammatory cascades [23,24]. Understanding these mechanisms sheds light on the profound impact of UV exposure on skin integrity, inflammation, and disease progression.

Upon UV exposure, keratinocytes experience oxidative stress, primarily due to the generation of reactive oxygen species (ROS) [25,26]. This oxidative environment is a critical starting point for TNF-α release. Research indicates that increased levels of ROS activate several intracellular signaling pathways, including the mitogen-activated protein kinase (MAPK) pathways, which are essential for mediating cytokine production, including TNF-α [27,28]. The activation of MAPK pathways leads to the phosphorylation of various proteins necessary for transcriptional changes in TNF-α and other pro-inflammatory cytokines. As a consequence of this signaling, keratinocytes increase the expression of TNF-α, promoting its release into the local environment [25,23].

Another important pathway activated by UV exposure is the nuclear factor kappa B (NF-κB) pathway. UV-induced apoptosis and stress signals facilitate the degradation of IκB proteins, which normally inhibit NF-κB from entering the nucleus [23]. Once freed, NF-κB translocates to the nucleus and binds to specific promoter regions of cytokine genes, including TNF-α. This transcriptional activation is critical, as it substantially enhances the production of TNF-α and other inflammatory mediators, thereby amplifying the inflammatory response following UV exposure [28,24].

In addition to ROS and NF-κB, the transcription factor activator protein-1 (AP-1) also plays a vital role in TNF-α release. UV radiation has been shown to stimulate the activation of AP-1, which can work synergistically with NF-κB to enhance the transcription of TNF-α [23,29]. The synergistic interaction between AP-1 and NF-κB illustrates the complexity of signaling networks activated in response to UV stress, emphasizing that multiple pathways converge to regulate TNF-α synthesis. This multifaceted approach is critical in managing tissue responses to UV damage and highlights the potential for intervention at different signaling points to mitigate inflammatory responses.

The release of TNF-α also elicits an autocrine mechanism whereby TNF-α can bind to its own receptors on keratinocytes, further enhancing the inflammatory response [26]. This creates a feedback loop that amplifies the release of additional inflammatory cytokines such as IL-1 and IL-6, exacerbating the inflammatory state within the skin. Such an autocrine signaling strategy allows for rapid and robust responses to sustained UV exposure, which can be crucial in orchestrating a defensive response to prevent more severe UV-induced damage [27,29]. However, chronic overproduction of TNF-α can contribute to persistent inflammation, which is implicated in several dermatological conditions, including psoriasis and skin cancer.

Moreover, the time and dose-dependent nature of TNF-α release following UV exposure cannot be overlooked. Studies have shown that TNF-α expression is significantly upregulated not only immediately following irradiation but continues to remain elevated for hours afterward, depending on the intensity and duration of UV exposure [30,31]. This temporal regulation suggests that keratinocytes adapt to UV stress over time, potentially leading to cumulative damage if protective mechanisms do not effectively counteract continual TNF-α signaling. Understanding this time-dependent response is critical for developing effective therapies aimed at mitigating the effects of UV-induced inflammation.

The mechanisms behind TNF-α release triggered by UV exposure involve a coordinated response driven by oxidative stress, activation of key transcription factors such as NF-κB and AP-1, and subsequent autocrine signaling processes. The interplay between these elements illustrates the complexity of UV-induced inflammatory responses in the skin. Effective management of TNF-α release and its downstream effects presents an appealing target for therapeutic intervention, particularly in inflammatory skin diseases exacerbated by UV radiation. As research continues to elucidate these mechanisms, strategies that mitigate TNF-α signaling or its effects may lead to improved outcomes in the treatment of UV-induced skin disease and aging [26,25,27,23].

C. Role of TNF-α in Activating Inflammatory Pathways and Oxidative Stress in the Skin

Tumor Necrosis Factor-alpha (TNF-α) is a central player in mediating inflammatory responses in the skin, particularly in the context of various dermatological conditions. It is primarily produced by activated macrophages and keratinocytes upon exposure to stimuli such as UV radiation, microbial infection, or injury. The significance of TNF-α lies in its ability to orchestrate multiple signaling pathways that can lead to inflammation and oxidative stress, which, while necessary for normal immune responses, can cause pathological changes when dysregulated [32,33]. Exploring the mechanisms by which TNF-α activates these pathways can reveal crucial insights into the underlying processes of skin inflammation and potential therapeutic targets for treatment.

Upon stimulation, TNF-α activates signaling pathways such as Nuclear Factor-kappa B (NF-κB) and Mitogen-Activated Protein Kinase (MAPK) pathways. The activation of NF-κB involves the phosphorylation and degradation of IκB proteins,

thus allowing NF-κB dimers to translocate to the nucleus and initiate the transcription of pro-inflammatory cytokines, including IL-1, IL-6, and further TNF-α itself [33]. This positive feedback loop promotes a sustained inflammatory response, reinforcing the initial insult and perpetuating tissue damage. On the other hand, the MAPK pathways, particularly the p38 MAPK and JNK pathways, mediate cellular responses to stress, including the production of additional inflammatory cytokines and the induction of apoptosis in severely damaged cells [33]. The persistent activation of these pathways contributes to chronic inflammation seen in skin diseases such as psoriasis and atopic dermatitis.

Furthermore, the release of TNF-α significantly correlates with oxidative stress levels in the skin. When TNF-α gene expression is upregulated, it triggers an increase in reactive oxygen species (ROS) production through various mechanisms, including the activation of membrane-bound NADPH oxidase complexes in neutrophils and keratinocytes [32]. Elevated oxidative stress further damages cellular components, leading to lipid peroxidation, protein modification, and DNA damage. These processes culminate in apoptosis and can exacerbate inflammatory conditions, thus creating a vicious cycle that hinders the skin's ability to repair itself and leads to the advancement of inflammatory skin disorders [32].

In conditions such as psoriasis, TNF-α has been implicated not only in initiating but also in perpetuating inflammation through its interaction with immune cells and keratinocytes. The dysregulated expression of TNF-α within psoriatic lesions contributes to a hyper-proliferative state of keratinocytes, characterized by increased turnover rates and abnormal differentiation [32,33]. This process is further enhanced by oxidative stress, which can alter cell signaling and gene expression profiles, perpetuating the cycle of inflammation and leading to the pathology observed in chronic skin conditions. Understanding these interactions is essential to developing effective therapeutic interventions targeting TNF-α pathways to alleviate symptoms and heal skin lesions.



FIGURE 2: Role of Tumor Necrosis Factor-alpha (TNF-α) in UV-induced skin aging. Ultraviolet (UV) radiation exposure results in the generation of reactive oxygen species (ROS), which can directly or indirectly activate intracellular signaling pathways. These pathways subsequently enhance TNF-α production. Elevated TNF-α stimulates the expression and activation of matrix metalloproteinases (MMPs), enzymes responsible for degrading type I and III collagen, thereby contributing to the aging process and loss of skin structural integrity.

Additionally, TNF-α exhibits bi-functional roles in different contexts, acting as both an ally and an enemy in the inflammatory landscape of the skin. While TNF-α is crucial for recruiting leukocytes to sites of inflammation and initiating the healing process following injury, excessive production can lead to pathological conditions [32].

In cases of chronic inflammatory diseases, the heightened levels of TNF-α not only promote inflammation but can also lead to adverse effects such as exacerbated oxidative stress and further rampant inflammatory responses. This duality emphasizes the importance of maintaining a balance in TNF-α levels and appropriately modulating its pathways for therapeutic purposes.

TNF-α plays a pivotal role in activating inflammatory pathways and oxidative stress in the skin. By initiating signaling mechanisms that activate NF-κB and MAPK pathways, TNF-α regulates the expression of other inflammatory mediators, creating a complex network that governs skin inflammation. While it is critical for the immune response, dysregulation of TNF-α production can lead to chronic skin conditions, amplifying oxidative stress and perpetuating inflammation. Targeting TNF-α through new therapeutic strategies holds promise for alleviating the burden of inflammatory skin diseases while potentially restoring skin homeostasis [32,33]. As ongoing research continues to clarify TNF-α's diverse roles in skin health and disease, it remains a significant focus for developing innovative treatments for various dermatological conditions.

LINK BETWEEN TNF-A AND HYPERPIGMENTATION

A. The Inflammatory Contribution to Melanogenesis

Melanogenesis, the process by which melanocytes produce melanin, is fundamentally influenced by numerous cytokines and signaling pathways, particularly in the context of inflammation. The skin, being the first line of defense against environmental stressors, encounters various inflammatory stimuli such as UV radiation, chemical exposure, and pathogens. These stimuli activate pathways that lead to the secretion of pro-inflammatory cytokines, which in turn modulate the activity of melanocytes and ultimately influence melanin production. Understanding the interplay between inflammation and melanogenesis is crucial, as it holds significant implications for skin disorders characterized by altered pigmentation, such as post-inflammatory hyperpigmentation and vitiligo [34,26].

One critical aspect of the inflammatory modulation of melanogenesis involves the secretion of cytokines from keratinocytes and fibroblasts in response to injury or stress [34]. Keratinocytes, for instance, release cytokines such as IL-1β and TNF-α upon UV exposure, which enhance the functional activity of melanocytes by upregulating melanogenesis-related enzymes, including tyrosinase and tyrosinase-related proteins (TRP-1 and TRP-2) [26]. This occurs through paracrine communication where keratinocyte-derived factors affect melanocyte behavior and coordinate a broader spectrum of responses aimed at protecting the skin from further damage. Consequently, the activation of melanocytes through inflammatory cytokines is a double-edged sword: it can enhance pigmentation as a protective mechanism, but excessive inflammation can lead to pathological pigmentation disorders.

The role of TNF-α in promoting melanogenesis further illustrates the intricate connection between inflammation and pigmentation. Research indicates that TNF-α stimulates melanin production through several pathways, including upregulation of microphthalmia-associated transcription factor (MITF), a master regulator of melanocyte differentiation and function. Moreover, TNF-α induces the production of various other signaling molecules that foster the proliferation and activation of melanocytes [35]. This process is particularly significant in conditions where inflammation is chronic, driving excessive melanin production that can lead to complications such as darkening of the skin or the formation of dermal nevi.

In the context of UV radiation, inflammatory responses are typically associated with an increase in melanin production, leading to tanning—a protective mechanism intended to shield underlying skin structures from further UV damage. The secretion of IL-1β following UV exposure has been shown to stimulate melanocytes, further promoting melanogenesis by enhancing the expression of tyrosinase and other melanogenic factors [26]. However, if the inflammatory response is excessive or prolonged, as is often observed in chronic inflammatory skin conditions, it can contribute to unwanted hyperpigmentation through the overactivation of melanocytes and keratinocytes alike.

While some inflammatory cytokines drive the expression of melanogenic factors, others exhibit inhibitory effects on melanogenesis. For example, IL-6, produced during inflammatory responses, has been reported to inhibit melanin synthesis, suggesting that the overall effect of inflammation on melanogenesis may depend on the balance and timing of cytokine release [36]. This highlights the complex nature of cytokine interactions in the skin, wherein different cytokines can have opposing effects on melanocyte behavior, leading to variability in pigmentation outcomes, especially during episodes of inflammation.

Creatively engaging with the implications of these findings leads to the consideration of therapeutic strategies targeting inflammatory pathways in the treatment of pigmentation disorders. By modulating the inflammatory response, clinically effective treatments could be developed to attenuate undesirable hyperpigmentation or encourage repigmentation in conditions such as vitiligo. For instance, topical applications of anti-inflammatory agents or cytokine inhibitors could provide a means to recalibrate the inflammatory landscape, potentially restoring balance to melanocyte activity and melanin production [37]. Furthermore, understanding these mechanisms could pave the way for more personalized dermatological treatments that consider the unique inflammatory profiles of individuals.

The contribution of inflammation to melanogenesis is a complex yet fundamental aspect of skin biology. Through the release of various cytokines and signaling pathways, inflammatory responses directly influence melanocyte function and melanin production. This intricate interplay has profound implications for our understanding of skin pigmentation disorders and highlights the need for targeted therapeutic approaches that consider the contributions of inflammation to pigmentary changes. Continued exploration of the mechanisms

governing inflammation and melanogenesis will be vital in developing effective strategies for managing cutaneous pigmentation disorders in clinical dermatology [34,26,38,37].

B. TNF-α as a Key Inflammatory Mediator Influencing the Expression and Activity of Tyrosinase Enzyme

Tumor Necrosis Factor-alpha (TNF-α) serves as a pivotal inflammatory mediator that significantly influences the expression and activity of the tyrosinase enzyme, a key regulator in the melanogenesis pathway. Melanogenesis is the biological process through which melanin is synthesized in melanocytes, determining pigmentation in skin, hair, and eyes. TNF-α is primarily produced in response to inflammatory stimuli, such as UV radiation, initiating complex signaling pathways that may enhance melanogenesis through modulation of enzyme activity, specifically tyrosinase [7]. Understanding the role of TNF-α in this context provides insights into the pathophysiology of various skin conditions characterized by abnormal pigmentation.

The mechanism by which TNF-α influences tyrosinase expression begins with its interaction with melanocytes. Upon binding to its receptors, TNF-α activates signaling pathways that include Nuclear Factor-kappa B (NF-κB) and Mitogen-Activated Protein Kinases (MAPKs) such as p38 MAPK and JNK [7]. These pathways converge to enhance the transcription of the tyrosinase gene, leading to increased enzyme production. Specifically, NF-κB activation has been shown to promote the expression of melanogenic factors, including microphthalmia-associated transcription factor (MITF), which is critical for the transcriptional regulation of not only tyrosinase but also other melanogenic enzymes [7,39]. This synergistic effect underscores the crucial role of TNF-α in modulating melanocyte activity in response to inflammation.

Experimental evidence illustrates that the increase in tyrosinase activity is not solely a result of elevated expression but is also linked to post-translational modifications facilitated by inflammatory signaling. The activation of TNF-α signaling can lead to a transient increase in tyrosinase enzymatic activity through phosphorylation events, enhancing the enzyme's ability to catalyze the conversion of tyrosine to dopa, the first step in melanin biosynthesis [40]. This regulatory mechanism highlights the dynamic nature of melanogenesis, reflecting how acute inflammatory responses can lead to significant changes in pigmentation.

Interestingly, while TNF-α promotes tyrosinase activity and melanogenesis, prolonged activation of inflammatory pathways can lead to dysregulated melanin production seen in conditions such as post-inflammatory hyperpigmentation and melasma. This phenomenon underscores the importance of maintaining a delicate balance in TNF-α signaling. Excessive levels of TNF-α can lead to chronic inflammation, which may overwhelm the normal regulatory mechanisms of melanocytes, pushing them towards a state of hyperactivity where melanin production is perpetually elevated [32]. Thus, a nuanced understanding of TNF-α's role can provide insights into potential therapeutic strategies for pigmentation disorders.

In the context of therapeutic approaches, targeting TNF-α signaling has emerged as a strategy for managing conditions characterized by abnormal pigmentation. Anti-inflammatory agents that inhibit TNF-α pathophysiological actions may help reduce excessive melanogenesis associated with chronic inflammatory states. For instance, inhibitors that block TNF-α signaling could not only alleviate inflammation but also restore normal tyrosinase expression levels [41]. Such targeted therapies could be instrumental in achieving desired skin pigmentation outcomes in patients suffering from conditions linked to dysregulated melanogenesis.

Additionally, exploring natural compounds that influence TNF-α levels offers a promising approach for ameliorating hyperpigmentation. Many bioactive flavonoids and plant extracts have been identified to attenuate both TNF-α production and its effects on melanogenesis [26,42]. These compounds can serve as potential adjuncts in topical formulations aimed at managing excessive pigmentation while providing additional protective benefits against UV-induced skin damage.

TNF-α serves as a critical inflammatory mediator influencing the expression and activity of the tyrosinase enzyme within melanocytes. Its activation leads to both an increase in tyrosinase expression and enzymatic activity, playing an important role in melanogenesis. However, caution must be exercised to control excessive TNF-α signaling that could result in pathological pigmentation disorders. Future research exploring the dual role of TNF-α in pigmentation regulation holds the potential to inform new strategies for treating various skin conditions associated with hyperpigmentation, providing innovative avenues for both prevention and therapy [7,39,40,32].

C. Regulation of Critical Melanogenic Genes (MITF, TRP-1, TRP-2) Mediated by TNF-α

Tumor Necrosis Factor-alpha (TNF-α) plays a significant role in regulating melanogenesis, particularly affecting critical melanogenic genes such as microphthalmia-associated transcription factor (MITF), tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2). These proteins are fundamental for melanin production in melanocytes and are instrumental in determining skin pigmentation. Under inflammatory conditions, such as those induced by exposure to UV radiation or other damaging stimuli, TNF-α can dramatically influence the expression and activity of these genes, highlighting their importance in the pathophysiology of skin pigmentation disorders [7,39].

MITF is often referred to as the master regulator of melanocyte function and is essential for the transcription of genes involved in melanin biosynthesis. TNF-α can modify the activity of MITF through various signaling pathways. For instance, TNF-α-induced activation of the NF-kB pathway has been shown to promote MITF transcription, leading to the upregulation of melanogenic enzymes [7]. Through this mechanism, TNF-α acts as a potent stimulator for the expression of TRP-1 and TRP-2, which are crucial for the stability and regulation of melanin synthesis. Thus, TNF-α emerges as an important modulator of the melanogenic pathway in response to inflammatory cues.

The regulation of TRP-1 and TRP-2 expression by TNF-α is critical for maintaining pigmentary homeostasis. TRP-1 enhances the enzymatic activity of tyrosinase, further contributing to melanin production, while TRP-2 is thought to stabilize the tyrosinase protein and increase the overall efficiency of melanogenesis [40]. As TNF-α signaling can enhance the expression of both TRP-1 and TRP-2, it serves as a central node that amplifies the overall pigmentation response in melanocytes during inflammatory states. This close interrelationship between TNF-α and melanogenic gene expression suggests that inflammatory mediators can have direct consequences on skin pigmentation, leading to either protective or pathological outcomes depending on the context and duration of the inflammatory response.

Studies have indicated that prolonged exposure to TNF-α may lead to dysregulation of these melanin-producing factors. Chronic inflammation can push the melanocyte response towards overproduction of melanin, ultimately resulting in conditions such as post-inflammatory hyperpigmentation or melasma [39]. In such cases, the sustained upregulation of MITF, alongside an imbalance in TRP-1 and TRP-2 expression, reflects an overactive melanogenic program that can lead to undesirable pigmentation changes. Understanding the fine balance of TNF-α signaling is therefore crucial in managing the outcomes of skin pigmentation disorders.

The involvement of TNF-α in melanogenic gene regulation also opens avenues for potential therapeutic strategies aimed at controlling hyperpigmentation. By targeting the TNF-α signaling pathway, it may be possible to downregulate MITF and its downstream effectors, thereby reducing the excessive melanogenic response [43]. For example, anti-TNF therapies or selective inhibitors of TNF-α signaling could provide an effective means to normalize the behavior of melanocytes in hyperpigmented skin conditions, offering a targeted approach that mitigates inflammation and restores pigmentary balance.

Additionally, TNF-α's interaction with other signaling molecules is an important aspect of its regulatory capacity. For instance, research has shown that TNF-α can modulate the activity of p38 MAPK, which also plays a role in the expression of MITF and other melanogenic genes [7,43]. This highlights a complex network where multiple pathways interact, ultimately influencing melanocyte function and pigmentation. The coordination of these pathways indicates that therapeutic interventions may need to consider the broader context of cytokine signaling when addressing pigmentation disorders.

TNF-α serves as a key inflammatory mediator that influences the regulation of critical melanogenic genes such as MITF, TRP-1, and TRP-2. By activating specific signaling pathways, TNF-α can increase the expression of these genes, driving the process of melanogenesis during inflammatory responses. However, dysregulated or chronic TNF-α signaling can lead to pathological pigmentation changes, emphasizing the need for careful modulation of its activity. Continuing research into the mechanisms by which TNF-α regulates melanogenic factors offers promising avenues for developing targeted therapies to manage skin pigmentation disorders effectively [39,43].



FIGURE 3: The schematic illustrates the central role of TNF-α in UV-induced skin hyperpigmentation. UV exposure triggers oxidative stress and keratinocyte activation, releasing inflammatory mediators including TNF-α. This cytokine stimulates NF-κB and MAPK signaling pathways, enhancing the expression of melanogenic genes (MITF, Tyrosinase, TRP-1, TRP-2, DCT). Subsequent increased melanin synthesis and sustained inflammatory feedback loop result in clinical hyperpigmentation, such as melasma and solar lentigo.

CURRENT EVIDENCE FROM PRECLINICAL AND CLINICAL STUDIES

Recent research in both preclinical and clinical studies has elucidated the role of TNF-α as a key inflammatory mediator influencing melanogenesis, particularly through the regulation of critical melanogenic genes such as MITF, TRP-1, and TRP-2. The understanding of these pathways has been shaped by a combination of in vitro studies using melanocyte cell cultures, in vivo animal studies investigating hyperpigmentation mechanisms, and clinical trials assessing TNF-α's involvement in hyperpigmentation among human subjects. These findings not only enhance our understanding of melanin regulation but also contribute to the development of targeted therapeutic approaches for pigmentary disorders.

A. In Vitro Studies Involving Melanocyte Cell Cultures

In vitro studies have provided valuable insights into how TNF-α affects melanocyte behavior. For instance, research has demonstrated that TNF-α treatment led to an increase in the expression of MITF, a master regulator of melanogenesis, in cultured human melanocyte-derived cells [1]. Furthermore, studies have highlighted the synergistic effect of TNF-α with interleukin-1 alpha, leading to increased oxidative stress and subsequent melanin production. This suggests that pro-inflammatory cytokines can work in concert to stimulate melanogenic pathways, proposing a potential mechanism through which skin inflammation contributes to altered pigmentation.

Additional research has identified the role of TNF-α in promoting the surface expression of proteins necessary for melanocyte adhesion and proliferation when co-cultured with keratinocytes [2]. This finding points to the complex interplay between inflammatory cytokines and cellular signaling in melanocyte biology, further substantiating the notion that TNF-α not only promotes melanin synthesis but also regulates melanocyte interactions with the surrounding skin architecture.

B. Animal (In Vivo) Studies Investigating Hyperpigmentation Pathways

In vivo, studies involving animal models have been essential for establishing the physiological relevance of TNF-α in hyperpigmentation pathways. A notable study showcased how administration of TNF-α in UV-exposed rats significantly increased melanin levels in the epidermis, correlating with heightened expression of MITF and associated melanogenic enzymes [1]. This model affirmed that TNF-α plays a substantial role in the inflammatory response to UV radiation and highlights the pathways through which inflammation can promote hyperpigmentation.

Further investigations have employed genetic models to explore the effects of TNF-α inhibition. Research demonstrated that blocking TNF-α signaling via specific antagonists resulted in a marked reduction of hyperpigmentation in skin exposed to inflammatory stimuli [3]. This suggests that the inflammatory environment plays a crucial role in regulating pigmentation, and targeting TNF-α could mitigate unwanted pigmentation changes, providing a clear link between inflammation and melanogenic activity.

C. Clinical Studies in Human Subjects Assessing TNF-α Involvement in Hyperpigmentation

Translating these findings to clinical settings, research involving human subjects has established that elevated levels of TNF-α are associated with conditions like melasma and post-inflammatory hyperpigmentation. Studies have shown that individuals with inflammatory skin conditions exhibit significantly heightened TNF-α levels correlating with increased melanin production [4]. This reinforces the notion that chronic inflammation can lead to sustained activation of melanogenic pathways, ultimately contributing to aberrant pigmentation.

Research focusing on vitiligo patients has shown that TNF-α levels were elevated in lesional skin, indicating a possible role in melanocyte apoptosis [5]. These findings highlight the complex role of TNF-α as both a promoter of melanogenesis in certain contexts while also contributing to melanocyte loss in others, further complicating the therapeutic landscape for hyperpigmentation disorders.

Moreover, studies have demonstrated that in subjects with proportional melasma, treatment with TNF-α inhibitors resulted in notable improvement in skin tone, reinforcing the potential of targeting TNF-α signaling to correct unwanted pigmentation [4]. This clinical evidence supports the idea that modulating TNF-α's effects could be a promising strategy for managing hyperpigmentation disorders effectively.

CLINICAL AND THERAPEUTIC IMPLICATIONS

The escalating incidence of skin hyperpigmentation disorders, such as melasma and post-inflammatory hyperpigmentation, necessitates new therapeutic approaches. Targeting Tumor Necrosis Factor-alpha (TNF-α) offers a promising avenue for managing these conditions, given its role as an inflammatory mediator that influences melanocyte activity and melanin production. By regulating key melanogenic genes such as MITF, TRP-1, and TRP-2, TNF-α serves as a critical factor in the pathophysiology of pigmentation disorders and presents a rational target for therapeutic intervention [32].

A. Potential of Targeting TNF-α for Therapeutic Management of Skin Hyperpigmentation

Antagonizing TNF-α's effects could prove beneficial for patients suffering from dyschromia caused by elevated inflammation. Inhibiting TNF-α may restore balance in the signaling pathways that regulate melanogenesis, thereby reducing excessive melanin synthesis triggered by inflammation. For instance, clinical applications of anti-TNF-α biologics, which have shown efficacy in treating autoimmune skin disorders, may provide dual benefits by alleviating inflammation and decreasing hyperpigmentation [41]. Such a dual-action approach could enhance overall skin health and aesthetic outcomes in individuals affected by pigmentation disorders.

B. Overview of Existing Anti-Inflammatory Agents with Potential Anti-TNF-α Activity

Several classes of anti-inflammatory agents have been investigated for their ability to inhibit TNF-α activity and alleviate its effects on skin pigmentation. Biological agents, such as monoclonal antibodies (e.g., infliximab and etanercept), specifically target TNF-α and have demonstrated effectiveness in various inflammatory skin conditions [41]. Their targeted actions offer a promising therapeutic avenue for hyperpigmentation by controlling the inflammatory environment without broadly suppressing the immune response.

In addition to biological agents, non-biological TNF-α inhibitors, such as certain NSAIDs, have been explored for their potential to modulate cytokine levels and may help mitigate TNF-α-mediated effects on the melanogenic process [44]. The identification and development of such non-biological agents could expand treatment options, particularly for patients who may not tolerate biological therapies.

C. Herbal Extracts with Anti-Inflammatory and Anti-Aging Benefits

Certain herbal extracts have garnered attention for their anti-inflammatory and anti-aging properties, including potential activity against TNF-α. For example, compounds from various plants have been identified as possessing significant anti-inflammatory effects, which may mitigate TNF-α mediated hyperpigmentation. Studies suggest that certain herbal extracts can reduce the levels of TNF-α and other pro-inflammatory cytokines while enhancing skin barrier health, potentially contributing to a reduction in pigmentation [26].

Other herbal compounds, such as curcumin and green tea extracts rich in polyphenols, have demonstrated properties that inhibit TNF-α signaling. These natural agents not only exhibit antioxidant activity but also offer protection against oxidative stress-induced melanogenesis, thereby presenting a holistic approach to managing pigmentation disorders through both anti-inflammatory and antioxidant strategies [45,42].

D. Integrating Targeted Therapies into Clinical Practice

Integrating these approaches targeting TNF-α with biological and non-biological agents while simultaneously employing herbal extracts could result in synergistic effects, enhancing the overall management of skin hyperpigmentation. The combined therapeutic strategy may allow for effective control of both inflammation and hyperpigmentation with potentially fewer side effects than conventional treatments [46].

Moreover, clinical practitioners can benefit from a multifaceted approach that tailors treatment based on individual patient profiles, considering both the severity of inflammatory responses and the patient's unique skin characteristics. This personalized medicine paradigm could optimize treatment outcomes and patient satisfaction, particularly in cases where standard therapies have proven inconsistent.

In conclusion, current evidence underscores TNF-α as a central player in the regulation of skin hyperpigmentation. The potential to target TNF-α provides a new therapeutic strategy for treating hyperpigmentation disorders through both traditional pharmaceuticals and innovative herbal solutions. Continued research into the mechanisms of TNF-α and its interactions with key melanogenic pathways will provide further insights into optimizing treatment protocols and improving clinical outcomes in patients with pigmentation disorders.

The integration of these anti-inflammatory interventions, whether biological, non-biological, or herbal, is pivotal in devising comprehensive strategies for the therapeutic management of skin hyperpigmentation, paving the way for enhanced dermatological care and improved patient quality of life [47,48].

CHALLENGES AND FUTURE RESEARCH DIRECTIONS

Despite the important findings related to TNF-α and its role in skin hyperpigmentation, existing research has several limitations that must be acknowledged. One major challenge is the limited amount of clinical data derived from human studies. Much of the current understanding of TNF-α's role in melanogenesis and hyperpigmentation is based on in vitro and animal studies, which may not always accurately replicate human physiological conditions or the complexities of human skin. The disparity between findings in preclinical models and human responses can potentially skew the development of effective treatments targeted at TNF-α regulation.

Moreover, many clinical studies that do exist often focus on the therapeutic efficacy of TNF-α inhibitors in broader inflammatory skin conditions rather than hyperpigmentation specifically. Consequently, there is a pressing need for targeted clinical trials that delve into the relationship between TNF-α levels and pigmentation outcomes in diverse patient populations.

Such studies could provide a clearer understanding of how TNF-α mediates hyperpigmentation and could assist in identifying vulnerable patient groups who may benefit from TNF-α-targeted therapies.

Another challenge lies in the variability of hyperpigmentation itself, which can arise from a multitude of factors, including genetic predisposition, environmental triggers, and the timing of inflammatory events. As noted by previous research, hyperpigmentation can result from different underlying mechanisms, sometimes exacerbated by inflammation mediated by TNF-α. Future studies should focus on stratifying subjects based on these factors to better understand how TNF-α's role may differ across populations and pigmentation disorders. This will not only help corroborate existing findings but also generate more personalized treatment protocols.

Beyond the need for more rigorous clinical trials, there is also an opportunity for more comprehensive molecular studies. Future research should investigate the specific molecular pathways through which TNF-α regulates melanogenic genes, including MITF, TRP-1, and TRP-2. Exploring the epigenetic modifications associated with TNF-α signaling could provide insights into how inflammatory responses can lead to persistent changes in melanocyte behavior and pigmentation.

Additionally, while the mechanisms by which TNF-α influences melanogenesis are of paramount interest, there is equally important work to be done examining potential therapeutic interventions that could balance TNF-α activity. Current therapies focusing on reducing TNF-α levels should be assessed comprehensively, particularly in combination with traditional skin-lightening agents such as hydroquinone or newer alternatives. Synergistic therapies that address both inflammation and pigmentary distress could lead to enhanced treatment outcomes for individuals suffering from hyperpigmentation.

In tandem with pharmacological approaches, exploring the potential of herbal extracts that exhibit anti-inflammatory and anti-TNF-α activities can lead to innovative combination therapies. For example, compounds that have shown promise in modulating inflammatory pathways while providing additional antioxidant benefits. Future studies should formally evaluate the efficacy of these natural remedies in conjunction with standard treatments, bringing a holistic approach to hyperpigmentation management into the forefront of dermatology.

Another increasingly relevant area for future exploration involves the integration of automated and objective measurement tools for assessing hyperpigmentation. The development of validated scoring systems would enable researchers to quantify the effectiveness of TNF-α-targeted treatments reliably. Improved methods for measuring hyperpigmentation could significantly enhance clinical trial designs and foster more robust data collection by standardizing outcome measures across studies.

CONCLUSION

The interaction between Tumor Necrosis Factor-alpha (TNF-α) and skin hyperpigmentation is a growing area of research that offers insights into the underlying inflammatory mechanisms involved in pigmentation disorders. This review highlights how TNF-α functions as a critical inflammatory mediator in ultraviolet (UV)-induced skin hyperpigmentation through its interactions with key melanogenic genes such as MITF, TRP-1, and TRP-2. The elevation of TNF-α in response to UV exposure triggers various signaling pathways that lead to increased melanin production, reflecting its dual role as a protector and potential contributor to skin discoloration under prolonged stress conditions [32].

Understanding the role of TNF-α in these melanogenic processes is essential for the development of effective therapeutic interventions for conditions associated with excessive pigmentation. Therapeutic strategies targeting TNF-α hold significant promise in managing hyperpigmentation by effectively controlling the inflammatory response and modulating the downstream effects on melanogenesis. Current research demonstrates that inhibiting TNF-α activity can reduce melanin synthesis and promote a more balanced skin tone [49]. The implications of such findings extend beyond superficial cosmetic concerns, as addressing TNF-α activity could also improve skin health by mitigating inflammation-related damage and promoting a more resilient skin barrier.

The evidence gathered from various preclinical and clinical studies helps to frame future research directions for dermatological management of hyperpigmentation. As highlighted, current limitations primarily revolve around the scarcity of robust clinical data concerning the direct impact of TNF-α modulation on hyperpigmentation. Thus, it is crucial to design and execute clinical trials that focus specifically on TNF-α blockade or inhibition in populations suffering from pigmentation disorders, as these could validate results observed in laboratory and animal models [46]. Emphasizing the need for multidisciplinary clinical designs will enhance our understanding of TNF-α's regulatory role and its broader implications in dermatology.

Among the recommended strategies for future research is the exploration of herbal extracts and naturally occurring compounds exhibiting anti-inflammatory properties. Compounds such as those found in various traditional medicines have shown promise in modulating TNF-α levels and melanin production. Rigorous studies assessing these compounds within clinical settings could provide insights into their effectiveness in mitigating hyperpigmentation through dual-action mechanisms of anti-inflammatory and antioxidative effects [41,50].

Additionally, an exploration of combined therapies that integrate traditional pharmaceutical TNF-α inhibitors with natural anti-inflammatory agents presents a compelling approach. The use of integrative strategies could optimize treatment outcomes by addressing both hyperpigmentation and the underlying inflammatory processes that exacerbate skin conditions. Personalized treatment protocols that consider individual patient profiles, including their inflammatory responses and genetic factors, may further enhance effectiveness [51,52].

In summary, a nuanced understanding of TNF-α's role in hyperpigmentation is essential for the advancement of clinical and therapeutic interventions. The complexity of inflammatory responses and their impact on melanogenesis underscores the importance of continued research aimed at elucidating these pathways. It is through such endeavors that effective treatments can be developed, improving the management of skin hyperpigmentation and promoting overall skin health. As the body of knowledge regarding TNF-α expands, so too will opportunities for innovative therapies that benefit patients suffering from various dermatological conditions linked to hyperpigmentation.

REFERENCES

[1] Zhou L, Wang H, Jing J, Yu L, Wu X, Zhang Z. A novel P53/POMC/Gαs/SASH1 autoregulatory feedback loop activates mutated SASH1 to cause pathologic hyperpigmentation. J Cell Mol Med. 2016;21(4):802-815.

[2] Kerns ML, DePianto D, Yamamoto M, Coulombe PA. Pathogenic and therapeutic role for NRF2 signaling in ultraviolet light induced skin pigmentation. JCI Insight. 2020;5(20):e139342.

[3] Manaka I, Sugimoto K, Takeuchi S, Furue M. The mechanism of hyperpigmentation in seborrhoeic keratosis involves the high expression of endothelin-converting enzyme-1alpha and TNF-alpha, which stimulate secretion of endothelin 1. Br J Dermatol. 2001;145(6):895-903.

[4] Nahhas AF, Scarbrough CA, Trotter S. The potential role of antioxidants in mitigating skin hyperpigmentation resulting from ultraviolet and visible light-induced oxidative stress. Photodermatol Photoimmunol Photomed. 2018;35(6):420-428.

[5] Meunier JR, Baudouin C, Ndiaye M, Soeur J, Tenenhaus A, Vázquez J, et al. Targeting SDF-1 as an efficient strategy to resolve skin hyperpigmentation issues with Himanthalia elongata extract. J Cosmet Dermatol. 2022;22(2):383-394.

[6] Vachiramon V, Thadanipon K, Suchonwanit P, Chanprapaph K. A study of botulinum toxin a for ultraviolet-induced hyperpigmentation: a randomized controlled trial. Dermatol Surg. 2021;47(5):e174-e178.

[7] Kim JA, Lim S, Jeong D, Kim Y, Choi S, Yoon H, et al. The pivotal role of osteopontin in UV-induced skin inflammation in a mouse model. Open Biol. 2024;14(11):230397.

[8] Kadono S, Manaka I, Kawashima M, Kobayashi T, Imokawa G. The role of the epidermal endothelin cascade in the hyperpigmentation mechanism of lentigo senilis. J Invest Dermatol. 2001;116(4):571-577.

[9] Rok J, Rokicka K, Buszman E, Wrześniok D, Beberok A. Molecular and biochemical basis of minocycline-induced hyperpigmentation the study on normal human melanocytes exposed to UVA and UVB radiation. Int J Mol Sci. 2021;22(7):3755.

[10] Lee YJ, Jeong HY, Kim YB, Lee YJ, Won SY, Shim JH, et al. Transglutaminase 2 mediates UV-induced skin inflammation by enhancing inflammatory cytokine production. Cell Death Dis. 2017;8(10):e3148.

[11] Lenain C, Bernard D, Martineau S, Sibon C, Gilson E, Serre G. Monitoring UV-induced signalling pathways in an ex vivo skin organ culture model using phospho-antibody array. Exp Dermatol. 2018;27(5):470-472.

[12] Gaddameedhi S, Selby CP, Kaufmann WK, Smart RC, Sancar A. The circadian clock controls sunburn apoptosis and erythema in mouse skin. J Invest Dermatol. 2015;135(4):1119-1127.

[13] Biniek K, Levi K, Dauskardt RH. Solar UV radiation reduces the barrier function of human skin. Proc Natl Acad Sci. 2012;109(42):17111-17116.

[14] Nazir Y, Hussain SA, Hameed A, Song J, Liu J, Ghouri MZ, et al. Inhibition of ultraviolet-B radiation induced photodamage by trigonelline through modulation of mitogen activating protein kinases and nuclear factor-κB signaling axis in skin. Photochem Photobiol. 2021;97(4):785-794.

[15] Song L, Turkson J, Karras JG, Jove R, Haura EB. P85α acts as a novel signal transducer for mediation of cellular apoptotic response to UV radiation. Mol Cell Biol. 2007;27(7):2713-2731.

[16] Fatmawati S, Risdiana E, Guntara AA, Zainuddin A. Royal jelly (bee product) decreases inflammatory response in wistar rats induced with ultraviolet radiation. Open Access Maced J Med Sci. 2019;7(17):2723-2727.

[17] Borská L, Kremlacek J, Andrys C, Krejsek J, Hamakova K, Borsky P, et al. Immunologic changes in TNF-alpha, sE-selectin, sP-selectin,

sICAM-1, and IL-8 in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol. 2007;24(6):607-612.

[18] Narbutt J, Norval M, Slowik-Rylska M, Jochymski C, Philipsen PA, Wulf HC, et al. Repeated doses of UVR cause minor alteration in cytokine serum levels in humans. Mediators Inflamm. 2005;2005(5):298-303.

[19] Laws SM, Hone E, Gandy S, Martins RN. TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Hum Mutat. 2005;26(1):29-35.

[20] Heimbach JK, Sanchez W, Rosen CB, Gores GJ. TNF receptor I is required for induction of macrophage heat shock protein 70. Am J Physiol Cell Physiol. 2001;281(1):C241-C247.

[21] Neam AA, Abd El-Kareem SA, Ebeido AM, Madkor HR. The effect of phototherapy on serum level of tumor necrosis factor alpha in neonates in Damietta governorate. Int J Med Arts. 2019;1(1):0-0.

[22] Skiba B, Neill B, Piva TJ, Vella LJ, Guillemin GJ. Gene expression profiles of TNF-α, TACE, furin, IL-1β and matrilysin in UVA- and UVB-irradiated HaCat cells. Photodermatol Photoimmunol Photomed. 2005;21(4):173-182.

[23] Bashir MM, Sharma MR, Werth VP. UVB and proinflammatory cytokines synergistically activate TNF-α production in keratinocytes through enhanced gene transcription. J Invest Dermatol. 2009;129(4):994-1001.

[24] Ortner D, Tripp CH, Komenda K, Weber F, Clausen BE, Stoitzner P. Langerhans cells orchestrate apoptosis of DNA-damaged keratinocytes upon high-dose UVB skin exposure. Eur J Immunol. 2024 ;54(12):2451020.

[25] Kim SH, Jun CD, Suk K, Choi BJ, Lim H, Park S, et al.2-O-β-D-glucopyranosyl-4,6-dihydroxybenzaldehyde isolated from Morus alba (mulberry) fruits suppresses damage by regulating oxidative and inflammatory responses in TNF-α-induced human dermal fibroblasts. Int J Mol Sci. 2022;23(23):14802.

[26] Yang B, Lim SI, Kim JC, Tran PT, Heo YS, Shin JA, et al. Antioxidant, anti-inflammation and antiaging activities of Artocarpus altilis methanolic extract on urban particulate matter-induced HaCaT keratinocytes damage. Antioxidants. 2022;11(11):2304.

[27] Choi BK, Kim JC, Jang YJ, Seo YK, Kim SK, Lee H, et al. The effects of flavonol and flavone glucuronides from Potentilla chinensis leaves on TNF-α-exposed normal human dermal fibroblasts. Antioxidants. 2023;12(10):1803.

[28] Jin J, Yu B, Shi Z, Wang C, Chong Y, Su X, et al. Preparation and evaluation of liposomes and niosomes containing total ginsenosides for anti-photoaging therapy. Front Bioeng Biotechnol. 2022;10:874827.

[29] Bruzzone S, Moreschi I, Usai C, Guida L, Damonte G, Salis A, et al. Autocrine abscisic acid mediates the UV-B-induced inflammatory response in human granulocytes and keratinocytes. J Cell Physiol. 2012;227(6):2502-2510.

[30] Liu X, Zhou J, Yu S, Chang X, Chen X, Yao X, et al. Time-and dose-dependent up-regulation of TNF-α mRNA after irradiation of human NSCLC cell lines in vitro. Chin J Cancer Res. 2006;18(1):19-25.

[31] Hanisch UK, Prinz M, Angstwurm K, Häusler KG, Kann O, Kettenmann H, et al. The protein tyrosine kinase inhibitor AG126 prevents the massive microglial cytokine induction by pneumococcal cell walls. Eur J Immunol. 2001;31(7):2104-2115.

[32] Pocino K, Vitiello M, Sansone C, Auriemma M, De Vita V, Sarti S, et al. Tumor necrosis factor-alpha: ally and enemy in protean cutaneous sceneries. Int J Mol Sci. 2024;25(14):7762.

[33] Schottelius AJ, Sägebiel S, Venne AS, Wenk J, Richter C, Altmeyer P. The role of mitogen-activated protein kinase-activated protein kinase 2 in the p38/TNF-α pathway of systemic and cutaneous inflammation. J Invest Dermatol. 2010;130(2):481-491.

[34] Kim J, Shin JH, Kim SY, Shin DM, Lee JL, Lee SY, et al. Photodynamic therapy inhibits melanogenesis through paracrine effects by keratinocytes and fibroblasts. Pigment Cell Melanoma Res. 2017;31(2):277-286.

[35] Kawabata K, Nakamura H, Sekiguchi M, Kanke Y, Mizutani J. Anti-inflammatory and anti-melanogenic steroidal saponin glycosides from fenugreek (Trigonella foenum-graecum L.) seeds. Planta Med. 2010;77(07):705-710.

[36] Zhao X, Zhou D, Liu Y, Li C, Zhao X, Li Y, et al. Critical role of metabotropic glutamate receptor 4 in bone marrow-derived dendritic cells in the Th17 cell differentiation and the melanogenesis of B16 cells. Braz J Med Biol Res. 2020;53(4):e9282.

[37] Dadachova E, Bryan RA, Huang X, Moadel T, Schweitzer AD, Aisen P, et al. Ionizing radiation changes the electronic properties of melanin and enhances the growth of melanized fungi. PLoS One. 2007;2(5):e457.

[38] Oh M, Ham I, Choi HY, Lee BH, Kim JY, Jang J, et al. Inhibitory effect of Korean red ginseng on melanocyte proliferation and its possible implication in GM-CSF mediated signaling. J Ginseng Res. 2013;37(4):389-400.

[39] Dutta M, Shome K, Singh B, Sinha P, Datta P, Roy A, et al. Identification of TNF-α as major susceptible risk locus for vitiligo: a systematic review and meta-analysis study in the Asian population. Dermatology. 2024;240(3):376-386.

[40] Kim JH, Ko JA, Kim JT, Cha DS, Cho JY, Kim HI, et al. Effect of 3,6-anhydro-L-galactose on α-melanocyte stimulating hormone-induced melanogenesis in human melanocytes and a skin-equivalent model. J Cell Biochem. 2018;119(9):7643-7656.

[41] Takaoka A, Arai I, Sugimoto M, Yamaguchi A, Tanaka M, Nakaike S. Inflammatory cytokine tumor necrosis factor-α enhances nerve growth factor production in human keratinocytes, HaCaT cells. J Pharmacol Sci. 2009;111(4):381-391.

[42] Ekowati J, Diyah NW, Nofianti T, Hamid IS, Siswodihardjo S, Achmad S. Potential utilization of phenolic acid compounds as anti-inflammatory agents through TNF-α convertase inhibition mechanisms: a network pharmacology, docking, and molecular dynamics approach. ACS Omega. 2023;8(49):46851-46868.

[43] Winarni D, Nurdiana N, Sari DRT, Maligan JM. Effect of serum breadfruit leaf extract (Artocarpus altilis) on TNF-α and SOD levels (experimental study on guinea pigs exposed to UVB light). Int J Multidiscip Res Anal. 2023;6(12):6037-6042.

[44] Leis T, Kohl A, Mirando AC, Mita C, Goisser A, Hartmann D, et al. Case report: malignant melanoma associated with COVID-19: a coincidence or a clue? Front Med. 2022;9:845558.

[45] Ågren MS, Schnabel R, Christensen LH, Mirastschijski U, Karlsmark T, Kjartansson H, et al. Tumor necrosis factor-α-accelerated degradation of type I collagen in human skin is associated with elevated matrix metalloproteinase (MMP)-1 and MMP-3 ex vivo. Eur J Cell Biol. 2015;94(1):12-21.

[46] Wu S, Luo X, Yang X, Yang K, Chen A, Chen S, et al. Efficacy of traditional Chinese medicines in the treatment of solar lentigo based on network pharmacology and experimental validation. J Cosmet Dermatol. 2024;23(12):4029-4042.

[47] Ashcroft GS, Jeong MJ, Ashworth JJ, Hardman M, Jin W, Moutsopoulos N, et al. Tumor necrosis factor-alpha (TNF-α) is a therapeutic target for impaired cutaneous wound healing. Wound Repair Regen. 2011;20(1):38-49.

[48] Nestlé FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J Exp Med. 2005;202(1):135-143.

[49] Almi AR, Salim H, Fatmawati S, Noviasty R. The effect of sapodilla leaf extract (Manilkara zapota L.P Royen) on IL-1 and TNF-α expression in male white rats wistar strain induced with UVB light. Int J Multidiscip Res Anal. 2024;7(2):862-868.

[50] Chimenti MS, Triggianese P, Perricone R. Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther. 2013;7:339-348.

[51] Nwikue CG, Adeyemi-Adeleye T, Alabi O, Chukwuma GO, Nwikue AE, Ugbaja CJ, et al. TNF-α induced extracellular release of keratinocyte high-mobility group box 1 in Stevens-Johnson syndrome/toxic epidermal necrolysis: biomarker and putative mechanism of pathogenesis. J Dermatol. 2023;50(9):1129-1139.

[52] Troya-Martín M, Vaño-Galván S, Fernández-Guarino M, Carrillo-Gijón R, Ruiz-Villaverde R, Garnacho-Saucedo G, et al. Personalized photoprotection: expert consensus and recommendations from a Delphi study among dermatologists. Photodermatol Photoimmunol Photomed. 2025;41(1):e70001.